PPARA and Insulin resistance: Among these drugs, three fibrates including bezafibrate, ciprofibrate, and etofibrate are used as lipid-lowering agents as well as PPAR agonists to treat hypercholesterolemia, hypertriglyceridemia, and reduce insulin resistance when the dyslipidemia is associated with other metabolic syndromes, for example, type 2 diabetes [30, 31].